Table 7 Meta-analysis of the studies performed in small cell lung cancer, with their characteristics

From: Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis

Group of SCLC ( n =4)

Study

Method

Threshold

QS (%)

N Pts

Bcl-2+ (%)

HR

95% CI

Dingemans et al (1999)

IHC-clone 100

>10

67

91

78

1.55

0.93–2.58

Kaiser et al (1996)

IHC

>50

63

146

75

0.76

0.55–1.04

Maitra et al (1999)

IHC-clone 100

>10

46

42

57

0.68

0.36–1.27

Takayama et al (1996)

IHC-clone 124

>10

55

38

55

1.31

0.64–2.70

Overall (fixed-effects model)

  

317

71

0.92

0.73–1.16

Overall (random-effects model)

    

0.99

0.66–1.48

χ2 statistic for heterogeneity=7.35, 3 df, P=0.06

  1. The meaning of the symbols is described in Table 3. IHC=Immunohistochemistry with other antibodies than clone 100 and 124.
Back to article page